\-\ Texto\\:\\ \ \(0\)\
\-\ exam\\:\\ thyroid\\ is\\ nontender\\,\\ left\\ lobe\\ visibly\\ larger\\ than\\ right\\,\\ soft\\ on\\ palpation\\,\\ normal\\ movement\\ during\\ swallow\\.\ \(0\)\
\-\ labs\\:\\ tsh\\ wnl\ \(0\)\
\-\ large\\ thyroid\\ nodule\\ with\\ fna\\ suspicious\\ for\\ papillary\\ vs\\ follicular\\ carcinoma\\.\\ \ \(0\)\
\-\ papillary\\ tc\\ ruled\\ out\\ by\\ intraoperative\\ frozen\\ section\\.\\ \\ definitive\\ diagnosis\\ unknown\\ at\\ time\\ of\\ case\\ compilation\\ pending\\ final\\ pathology\\ report\\.\ \(0\)\
\-\ this\\ patient\\ underwent\\ a\\ hemithyroidectomy\\ during\\ the\\ second\\ trimester\\.\\ \\ she\\ may\\ undergo\\ removal\\ of\\ her\\ remaining\\ thyroid\\,\\ followed\\ by\\ post\\-partum\\ radioiodine\\ ablation\\,\\ depending\\ on\\ the\\ final\\ pathology\\ report\\.\ \(0\)\
\-\ within\\ the\\ mid\\ to\\ lower\\ pole\\ of\\ the\\ left\\ lobe\\,\\ there\\ is\ \(0\)\
\-\ a\\ large\\ predominantly\\ solid\\ nodule\\ with\\ a\\ small\\ cystic\\ component\\ superiorly\\.\\ this\\ nodule\\ measures\\ 2\\.6\\ x\\ 2\\.1\\ x\\ 3\\.8\\ cm\\.\\ \\ no\\ microcalcifications\\.\\ \\ some\\ intranodular\\ vascularity\\,\\ primarily\\ peripheral\\.\\ \\ nodule\\ margins\\ are\\ smooth\\ and\\ well\\ defined\\.\ \(0\)\
\-\ thyroid\\ cancer\\,\\ probably\\ follicular\ \(0\)\
\-\ adenoma\ \(519\)\
\-\ \\ \\-macrofollicular\\ adenoma\ \(0\)\
\-\ \\ \\-microfollicular\\ adenoma\ \(0\)\
\-\ \\ \\-embryonal\\ adenoma\ \(0\)\
\-\ \\ \\-hurthle\\ cell\\ adenoma\ \(0\)\
\-\ \\ \\-atypical\\ adenoma\ \(0\)\
\-\ \\ \\-signet\\-ring\\ adenoma\ \(0\)\
\-\ carcinoma\ \(1182\)\
\-\ \\ \\-papillary\ \(0\)\
\-\ \\ \\-follicular\ \(0\)\
\-\ \\ \\-medullary\ \(2\)\
\-\ \\ \\-anaplastic\ \(0\)\
\-\ \\ \\-metastasis\ \(0\)\
\-\ \\ \\-thyroid\\ lymphoma\ \(0\)\
\-\ colloid\\ nodule\ \(0\)\
\-\ inflammatory\\ process\ \(22\)\
\-\ 27\\ y\\/o\\ woman\\ with\\ known\\ thyroid\\ asymmetry\\ x\\ 2\\ years\\,\\ presents\\ for\\ initial\\ prenatal\\ appointment\\.\\ \\ no\\ previous\\ workup\\ for\\ gland\\ asymmetry\\.\\ \\ patient\\ denies\\ hypo\\/hyperthyroid\\ symptoms\\.\\ \\ hx\\ negative\\ for\\ neck\\ irradiation\\.\ \(0\)\
\-\ this\\ case\\ highlights\\ the\\ differences\\ in\\ decision\\ making\\ for\\ the\\ pregnant\\ patient\\ with\\ a\\ newly\\ diagnosed\\,\\ asymptomatic\\ thyroid\\ nodule\\.\\ one\\ may\\ postpone\\ workup\\ in\\ the\\ euthymic\\ pregnant\\ patient\\ up\\ to\\ one\\ year\\ from\\ time\\ of\\ nodule\\ discovery\\ without\\ affecting\\ her\\ outcome\\.\\ \\ a\\ postpartum\\ workup\\ allows\\ for\\ additional\\ tests\\ such\\ as\\ radioactive\\ iodine\\ uptake\\,\\ although\\ these\\ tests\\ are\\ of\\ negligible\\ value\\ in\\ the\\ euthymic\\ patient\\.\ \(0\)\
\-\ if\\ the\\ nodule\\ is\\ worked\\ up\\ early\\ in\\ pregnancy\\ and\\ treatment\\ requires\\ surgical\\ removal\\ of\\ the\\ nodule\\,\\ the\\ patient\\ must\\ decide\\ whether\\ to\\ proceed\\ with\\ surgery\\ during\\ or\\ after\\ pregnancy\\.\\ \\ the\\ second\\ trimester\\ is\\ the\\ preferred\\ time\\ to\\ undergo\\ elective\\ procedures\\;\\ procedures\\ at\\ surgical\\ sites\\ remote\\ to\\ the\\ abdomen\\ are\\ considered\\ especially\\ low\\ risk\\ to\\ the\\ fetus\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ however\\,\\ if\\ the\\ newly\\ diagnosed\\ patient\\ prefers\\ to\\ postpone\\ surgery\\ until\\ the\\ postpartum\\ period\\,\\ she\\ may\\ do\\ so\\ without\\ affecting\\ her\\ outcome\\,\\ even\\ if\\ she\\ has\\ thyroid\\ malignancy\\ with\\ local\\ lymph\\ node\\ mets\\.\ \(0\)\
\-\ \\ \\ \ \(31891\)\
\-\ the\\ pregnant\\ patient\\ who\\ requires\\ radioiodine\\ ablation\\ following\\ surgery\\ must\\ wait\\ to\\ undergo\\ ria\\ until\\ she\\ is\\ not\\ only\\ postpartum\\,\\ but\\ no\\ longer\\ breast\\ feeding\\ and\\ has\\ significanly\\ reduced\\ lactation\\.\\ \\ otherwise\\,\\ ria\\ may\\ increase\\ her\\ risk\\ of\\ breast\\ cancer\\ later\\ in\\ life\\.\ \(0\)\
\-\ \\ \\ \ \(31891\)\
\-\ references\\:\\ \ \(0\)\
\-\ the\\ american\\ thyroid\\ association\\ guidelines\\ taskforce\\:\\ revised\\ american\\ thyroid\\ association\\ management\\ guidelines\\ for\\ patients\\ with\\ thyroid\\ nodules\\ and\\ differentiated\\ thyroid\\ cancer\\;\\ thyroid\\ vol\\.\\ 19\\,\\ no\\.\\ 11\\,\\ 2009\\.\ \(0\)\
\-\ blum\\:\\ ultrasonography\\ of\\ the\\ thyroid\\;\\ thyroidmanager\\.org\\.\\ updated\\ january\\ 2009\\.\ \(0\)\
\-\ \\Â\\ \ \(347\)\
\-\ moosa\\ and\\ mazzaferri\\:\\ outcome\\ of\\ differentiated\\ thyroid\\ cancer\\ diagnosed\\ in\\ pregnant\\ women\\;\\ jcem\\ vol\\.\\ 82\\,\\ no\\.\\ 9\\.\\ printed\\ in\\ u\\.s\\.a\\.\\ copyright\\ \\Â\\©\\ 1997\\.\ \(0\)\
\-\ \\Â\\ \ \(347\)\
\-\ welker\\ and\\ orlov\\:\\ thyroid\\ nodules\\;\\ afp\\ vol\\.\\ 67\\,\\ no\\.\\ 3\\,\\ february\\ 2003\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroid\\:\\ 0\\.10122290303250608\ \(0\)\
\-\ nodule\\:\\ 0\\.061078848541768885\ \(0\)\
\-\ adenoma\\:\\ 0\\.04812998162358783\ \(0\)\
\-\ pregnant\\:\\ 0\\.038777100501335156\ \(0\)\
\-\ postpartum\\:\\ 0\\.0357020872505852\ \(0\)\
\-\ postpone\\:\\ 0\\.03397116926384007\ \(0\)\
\-\ euthymic\\:\\ 0\\.03397116926384007\ \(0\)\
\-\ ria\\:\\ 0\\.03397116926384007\ \(0\)\
\-\ vol\\:\\ 0\\.03308945647750394\ \(0\)\
\-\ outcome\\:\\ 0\\.029491019406139827\ \(0\)\
\-\ 2009\\.\\:\\ 0\\.0270665084961019\ \(0\)\
\-\ radioiodine\\:\\ 0\\.026472478901391847\ \(0\)\
\-\ workup\\:\\ 0\\.02541432263682023\ \(0\)\
\-\ undergo\\:\\ 0\\.025076194274498795\ \(0\)\
\-\ guidelines\\:\\ 0\\.02305319876651361\ \(0\)\
\-\ newly\\:\\ 0\\.021888339915365505\ \(0\)\
\-\ follicular\\:\\ 0\\.021724333694098468\ \(0\)\
\-\ cancer\\:\\ 0\\.021650599339998192\ \(0\)\
\-\ trimester\\:\\ 0\\.02141588395354534\ \(0\)\
\-\ ablation\\:\\ 0\\.02061573225883149\ \(0\)\
\-\ asymmetry\\:\\ 0\\.02061573225883149\ \(0\)\
\-\ her\\:\\ 0\\.019802787348631487\ \(0\)\
\-\ \\;\\:\\ 0\\.019512728212452733\ \(0\)\
\-\ she\\:\\ 0\\.018487754462074544\ \(0\)\
\-\ affecting\\:\\ 0\\.018323990032447317\ \(0\)\
\-\ diagnosed\\:\\ 0\\.018162977784942226\ \(0\)\
\-\ procedures\\:\\ 0\\.01782606428493284\ \(0\)\
\-\ final\\:\\ 0\\.017768114853855616\ \(0\)\
\-\ differentiated\\:\\ 0\\.01759931862010458\ \(0\)\
\-\ requires\\:\\ 0\\.017490760327362014\ \(0\)\
\-\ tests\\:\\ 0\\.01723203469022279\ \(0\)\
\-\ intranodular\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ \\-macrofollicular\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ \\-microfollicular\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ \\-embryonal\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ \\-hurthle\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ \\-signet\\-ring\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ \\-papillary\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ \\-metastasis\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ hypo\\/hyperthyroid\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ negligible\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ significanly\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ taskforce\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ thyroidmanager\\.org\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ moosa\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ mazzaferri\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ jcem\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ printed\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ u\\.s\\.a\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ \\Â\\©\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ welker\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ orlov\\:\\ 0\\.016985584631920035\ \(0\)\
\-\ papillary\\:\\ 0\\.016717462849665864\ \(0\)\
\-\ x\\:\\ 0\\.01629518112917617\ \(0\)\
\-\ association\\:\\ 0\\.01600030570271457\ \(0\)\
\-\ american\\:\\ 0\\.015686267035079953\ \(0\)\
\-\ hemithyroidectomy\\:\\ 0\\.01565004093141918\ \(0\)\
\-\ \\-atypical\\:\\ 0\\.01565004093141918\ \(0\)\
\-\ \\-follicular\\:\\ 0\\.01565004093141918\ \(0\)\
\-\ \\-anaplastic\\:\\ 0\\.01565004093141918\ \(0\)\
\-\ blum\\:\\ 0\\.01565004093141918\ \(0\)\
\-\ \\:\\:\\ 0\\.015244554358255598\ \(0\)\
\-\ during\\:\\ 0\\.015115660404183861\ \(0\)\
\-\ must\\:\\ 0\\.015011705195138239\ \(0\)\
\-\ compilation\\:\\ 0\\.014868797948551808\ \(0\)\
\-\ \\-thyroid\\:\\ 0\\.014868797948551808\ \(0\)\
\-\ lactation\\:\\ 0\\.014868797948551808\ \(0\)\
\-\ report\\:\\ 0\\.014740215172207175\ \(0\)\
\-\ until\\:\\ 0\\.014462132527705323\ \(0\)\
\-\ may\\:\\ 0\\.01444569070441714\ \(0\)\
\-\ copyright\\:\\ 0\\.014314497230918318\ \(0\)\
\-\ pregnancy\\:\\ 0\\.014157436868839452\ \(0\)\
\-\ time\\:\\ 0\\.01395145218057406\ \(0\)\
\-\ visibly\\:\\ 0\\.013884548191777259\ \(0\)\
\-\ \\-medullary\\:\\ 0\\.013884548191777259\ \(0\)\
\-\ prefers\\:\\ 0\\.013884548191777259\ \(0\)\
\-\ nodules\\:\\ 0\\.013651325107525054\ \(0\)\
\-\ wait\\:\\ 0\\.01353325424805095\ \(0\)\
\-\ 1997\\.\\:\\ 0\\.01353325424805095\ \(0\)\
\-\ pathology\\:\\ 0\\.013477450597773725\ \(0\)\
\-\ if\\:\\ 0\\.013403141235726215\ \(0\)\
\-\ revised\\:\\ 0\\.013236239450695924\ \(0\)\
\-\ patient\\:\\ 0\\.013203729185609064\ \(0\)\
\-\ removal\\:\\ 0\\.012981815230443883\ \(0\)\
\-\ decide\\:\\ 0\\.012978953530417461\ \(0\)\
\-\ proceed\\:\\ 0\\.01275201126518358\ \(0\)\
\-\ second\\:\\ 0\\.012647895704196447\ \(0\)\
\-\ 3\\.8\\:\\ 0\\.012549004491276402\ \(0\)\
\-\ highlights\\:\\ 0\\.012549004491276402\ \(0\)\
\-\ differences\\:\\ 0\\.012549004491276402\ \(0\)\
\-\ frozen\\:\\ 0\\.012365362526335506\ \(0\)\
\-\ post\\-partum\\:\\ 0\\.01219771054755009\ \(0\)\
\-\ breast\\:\\ 0\\.012148585525358583\ \(0\)\
\-\ irradiation\\:\\ 0\\.012043485677273529\ \(0\)\
\-\ updated\\:\\ 0\\.012043485677273529\ \(0\)\
\-\ surgery\\:\\ 0\\.01199421424485708\ \(0\)\
\-\ risk\\:\\ 0\\.011927578602539832\ \(0\)\
\-\ february\\:\\ 0\\.011767761508409032\ \(0\)\
\-\ discovery\\:\\ 0\\.011643409829916603\ \(0\)\
\-\ tc\\:\\ 0\\.011526599383256805\ \(0\)\
\-\ appointment\\:\\ 0\\.011526599383256805\ \(0\)\
\-\ radioactive\\:\\ 0\\.011526599383256805\ \(0\)\
\-\ \\,\\:\\ 0\\.011475185821542047\ \(0\)\
\-\ worked\\:\\ 0\\.011312291801156182\ \(0\)\
\-\ january\\:\\ 0\\.011213460790775544\ \(0\)\
\-\ fna\\:\\ 0\\.011119452767327696\ \(0\)\
\-\ 2\\.1\\:\\ 0\\.011119452767327696\ \(0\)\
\-\ elective\\:\\ 0\\.011119452767327696\ \(0\)\
\-\ microcalcifications\\:\\ 0\\.011029818825834647\ \(0\)\
\-\ intraoperative\\:\\ 0\\.010862166847049234\ \(0\)\
\-\ 2\\.6\\:\\ 0\\.010862166847049234\ \(0\)\
\-\ decision\\:\\ 0\\.01070794197677267\ \(0\)\
\-\ ultrasonography\\:\\ 0\\.01070794197677267\ \(0\)\
\-\ iodine\\:\\ 0\\.010369038958538251\ \(0\)\
\-\ 82\\:\\ 0\\.010191055682755948\ \(0\)\
\-\ allows\\:\\ 0\\.01013520301055315\ \(0\)\
\-\ afp\\:\\ 0\\.01013520301055315\ \(0\)\
\-\ no\\:\\ 0\\.00994733122200927\ \(0\)\
\-\ 67\\:\\ 0\\.009877917090274685\ \(0\)\
\-\ for\\:\\ 0\\.009833828594410416\ \(0\)\
\-\ preferred\\:\\ 0\\.00978390906682684\ \(0\)\
\-\ colloid\\:\\ 0\\.009694275125333789\ \(0\)\
\-\ 9\\.\\:\\ 0\\.009650974825040806\ \(0\)\
\-\ swallow\\:\\ 0\\.009608626257181894\ \(0\)\
\-\ fetus\\:\\ 0\\.009608626257181894\ \(0\)\
\-\ remote\\:\\ 0\\.009526623146548377\ \(0\)\
\-\ mets\\:\\ 0\\.009486894269471814\ \(0\)\
\-\ value\\:\\ 0\\.009335696551858143\ \(0\)\
\-\ carcinoma\\:\\ 0\\.009333054605070777\ \(0\)\
\-\ longer\\:\\ 0\\.009299680881314496\ \(0\)\
\-\ ruled\\:\\ 0\\.009161995016223659\ \(0\)\
\-\ superiorly\\:\\ 0\\.009161995016223659\ \(0\)\
\-\ making\\:\\ 0\\.009129057765049669\ \(0\)\
\-\ vascularity\\:\\ 0\\.009096674107407318\ \(0\)\
\-\ sites\\:\\ 0\\.008972322428914886\ \(0\)\
\-\ tsh\\:\\ 0\\.008942449237130752\ \(0\)\
\-\ prenatal\\:\\ 0\\.008942449237130752\ \(0\)\
\-\ one\\:\\ 0\\.00892382035957859\ \(0\)\
\-\ lobe\\:\\ 0\\.008860598643250613\ \(0\)\
\-\ whether\\:\\ 0\\.00885551198225509\ \(0\)\
\-\ up\\:\\ 0\\.008854902316201245\ \(0\)\
\-\ section\\:\\ 0\\.008827383274314525\ \(0\)\
\-\ probably\\:\\ 0\\.00877232860679226\ \(0\)\
\-\ reduced\\:\\ 0\\.008666725068266259\ \(0\)\
\-\ primarily\\:\\ 0\\.008641204400154465\ \(0\)\
\-\ remaining\\:\\ 0\\.00856660996435352\ \(0\)\
\-\ depending\\:\\ 0\\.00856660996435352\ \(0\)\
\-\ nontender\\:\\ 0\\.008448365366325981\ \(0\)\
\-\ wnl\\:\\ 0\\.008448365366325981\ \(0\)\
\-\ feeding\\:\\ 0\\.008448365366325981\ \(0\)\
\-\ 2003\\:\\ 0\\.008273082556681036\ \(0\)\
\-\ movement\\:\\ 0\\.008231644781688814\ \(0\)\
\-\ hx\\:\\ 0\\.008151350568970955\ \(0\)\
\-\ definitive\\:\\ 0\\.008131789159599053\ \(0\)\
\-\ women\\:\\ 0\\.008000152851357285\ \(0\)\
\-\ larger\\:\\ 0\\.007928782385691873\ \(0\)\
\-\ suspicious\\:\\ 0\\.007928782385691873\ \(0\)\
\-\ without\\:\\ 0\\.0077534226063898275\ \(0\)\
\-\ predominantly\\:\\ 0\\.007713553118678382\ \(0\)\
\-\ period\\:\\ 0\\.007697951557536534\ \(0\)\
\-\ pole\\:\\ 0\\.007667122383458613\ \(0\)\
\-\ 27\\:\\ 0\\.007636778728414029\ \(0\)\
\-\ 19\\:\\ 0\\.007592140849258857\ \(0\)\
\-\ local\\:\\ 0\\.00756294661993207\ \(0\)\
\-\ node\\:\\ 0\\.007534188141672579\ \(0\)\
\-\ 11\\:\\ 0\\.007534188141672579\ \(0\)\
\-\ component\\:\\ 0\\.007519968281754232\ \(0\)\
\-\ so\\:\\ 0\\.007491839573813668\ \(0\)\
\-\ margins\\:\\ 0\\.007477927728007334\ \(0\)\
\-\ even\\:\\ 0\\.0073311813677654\ \(0\)\
\-\ smooth\\:\\ 0\\.00720682968927297\ \(0\)\
\-\ case\\:\\ 0\\.007204256003342084\ \(0\)\
\-\ large\\:\\ 0\\.007200548870254642\ \(0\)\
\-\ life\\:\\ 0\\.00718289419794627\ \(0\)\
\-\ do\\:\\ 0\\.007147539402824504\ \(0\)\
\-\ pending\\:\\ 0\\.00712432487774517\ \(0\)\
\-\ measures\\:\\ 0\\.007045208332855432\ \(0\)\
\-\ gland\\:\\ 0\\.007012271081681443\ \(0\)\
\-\ denies\\:\\ 0\\.006948039058044465\ \(0\)\
\-\ defined\\:\\ 0\\.006937538856180178\ \(0\)\
\-\ surgical\\:\\ 0\\.0069218565327609\ \(0\)\
\-\ increase\\:\\ 0\\.006906377277672277\ \(0\)\
\-\ mid\\:\\ 0\\.006885879400591244\ \(0\)\
\-\ references\\:\\ 0\\.006845526464473242\ \(0\)\
\-\ especially\\:\\ 0\\.006776880650131911\ \(0\)\
\-\ are\\:\\ 0\\.006733374985720241\ \(0\)\
\-\ considered\\:\\ 0\\.006646517165596622\ \(0\)\
\-\ lymph\\:\\ 0\\.006646517165596622\ \(0\)\
\-\ additional\\:\\ 0\\.006602016751734099\ \(0\)\
\-\ to\\:\\ 0\\.00658293808775316\ \(0\)\
\-\ solid\\:\\ 0\\.006567141912343698\ \(0\)\
\-\ uptake\\:\\ 0\\.006541393881877094\ \(0\)\
\-\ vs\\:\\ 0\\.006482620366860882\ \(0\)\
\-\ unknown\\:\\ 0\\.0064255867064056\ \(0\)\
\-\ previous\\:\\ 0\\.006393738340410975\ \(0\)\
\-\ malignancy\\:\\ 0\\.0063624078570356755\ \(0\)\
\-\ process\\:\\ 0\\.00633923985517286\ \(0\)\
\-\ management\\:\\ 0\\.006212970025926091\ \(0\)\
\-\ has\\:\\ 0\\.006183814915199529\ \(0\)\
\-\ early\\:\\ 0\\.006021500904898724\ \(0\)\
\-\ peripheral\\:\\ 0\\.005957482316019494\ \(0\)\
\-\ later\\:\\ 0\\.00594492994410968\ \(0\)\
\-\ otherwise\\:\\ 0\\.00591390218386579\ \(0\)\
\-\ labs\\:\\ 0\\.00572634683417175\ \(0\)\
\-\ inflammatory\\:\\ 0\\.005709664632354574\ \(0\)\
\-\ in\\:\\ 0\\.0056835849922577735\ \(0\)\
\-\ underwent\\:\\ 0\\.005649703343888669\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.005565688628123482\ \(0\)\
\-\ although\\:\\ 0\\.005560557380687098\ \(0\)\
\-\ this\\:\\ 0\\.005555706435341809\ \(0\)\
\-\ followed\\:\\ 0\\.005519992045045803\ \(0\)\
\-\ palpation\\:\\ 0\\.005495065665410505\ \(0\)\
\-\ by\\:\\ 0\\.005483124867995664\ \(0\)\
\-\ initial\\:\\ 0\\.005455842279921595\ \(0\)\
\-\ out\\:\\ 0\\.005441336949631052\ \(0\)\
\-\ is\\:\\ 0\\.0054170595220108435\ \(0\)\
\-\ the\\:\\ 0\\.00532752542210504\ \(0\)\
\-\ known\\:\\ 0\\.00521011769646208\ \(0\)\
\-\ such\\:\\ 0\\.005147076666360024\ \(0\)\
\-\ some\\:\\ 0\\.004999861760822272\ \(0\)\
\-\ only\\:\\ 0\\.004950696837157872\ \(0\)\
\-\ negative\\:\\ 0\\.004917379887042147\ \(0\)\
\-\ abdomen\\:\\ 0\\.0048774263254252334\ \(0\)\
\-\ years\\:\\ 0\\.004834765196567403\ \(0\)\
\-\ neck\\:\\ 0\\.004834765196567403\ \(0\)\
\-\ cystic\\:\\ 0\\.004748810611275064\ \(0\)\
\-\ lymphoma\\:\\ 0\\.004705585037359317\ \(0\)\
\-\ following\\:\\ 0\\.004672982190560979\ \(0\)\
\-\ however\\:\\ 0\\.00458452419190187\ \(0\)\
\-\ low\\:\\ 0\\.004578358483364932\ \(0\)\
\-\ y\\/o\\:\\ 0\\.004559978862850945\ \(0\)\
\-\ at\\:\\ 0\\.004461515039813614\ \(0\)\
\-\ cell\\:\\ 0\\.0044474772862841735\ \(0\)\
\-\ cm\\:\\ 0\\.004416100419685907\ \(0\)\
\-\ than\\:\\ 0\\.004314159643387811\ \(0\)\
\-\ who\\:\\ 0\\.004292810036881892\ \(0\)\
\-\ these\\:\\ 0\\.004284864531710675\ \(0\)\
\-\ patients\\:\\ 0\\.004261222734809298\ \(0\)\
\-\ symptoms\\:\\ 0\\.004103386275333601\ \(0\)\
\-\ soft\\:\\ 0\\.0040094928015289985\ \(0\)\
\-\ 3\\:\\ 0\\.0038554441747717526\ \(0\)\
\-\ a\\:\\ 0\\.0038208073392928827\ \(0\)\
\-\ woman\\:\\ 0\\.0038032812090345014\ \(0\)\
\-\ small\\:\\ 0\\.003793015962198687\ \(0\)\
\-\ diagnosis\\:\\ 0\\.003780769423469017\ \(0\)\
\-\ well\\:\\ 0\\.0037246261136197516\ \(0\)\
\-\ lower\\:\\ 0\\.003703009767560429\ \(0\)\
\-\ left\\:\\ 0\\.0036844133690671086\ \(0\)\
\-\ exam\\:\\ 0\\.003617021078900844\ \(0\)\
\-\ 2\\:\\ 0\\.003545480725453846\ \(0\)\
\-\ but\\:\\ 0\\.0035115670540145235\ \(0\)\
\-\ after\\:\\ 0\\.0034065533768963437\ \(0\)\
\-\ presents\\:\\ 0\\.003363476484601013\ \(0\)\
\-\ treatment\\:\\ 0\\.0033325952978822486\ \(0\)\
\-\ within\\:\\ 0\\.00314090830132193\ \(0\)\
\-\ on\\:\\ 0\\.0027895607412925937\ \(0\)\
\-\ normal\\:\\ 0\\.0025811415310194627\ \(0\)\
\-\ as\\:\\ 0\\.0024905154256148897\ \(0\)\
\-\ there\\:\\ 0\\.0024503189912620208\ \(0\)\
\-\ from\\:\\ 0\\.002440145882763415\ \(0\)\
\-\ not\\:\\ 0\\.0023792267278264652\ \(0\)\
\-\ \\.\\:\\ 0\\.0021887960599519863\ \(0\)\
\-\ and\\:\\ 0\\.0020810289680025253\ \(0\)\
\-\ of\\:\\ 0\\.002020297123664539\ \(0\)\
\-\ or\\:\\ 0\\.001929716279313502\ \(0\)\
\-\ year\\:\\ 0\\.0018422066845335543\ \(0\)\
\-\ right\\:\\ 0\\.001737247994432402\ \(0\)\
\-\ with\\:\\ 0\\.0015780910069927323\ \(0\)\
